Working… Menu
Trial record 1 of 1 for:    GEMCAD 17-01
Previous Study | Return to List | Next Study

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal (BEYOND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03751176
Recruitment Status : Recruiting
First Posted : November 23, 2018
Last Update Posted : February 19, 2020
Pivotal S.L.
Information provided by (Responsible Party):
Grupo Espanol Multidisciplinario del Cancer Digestivo

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 30, 2020
Estimated Study Completion Date : November 30, 2022